



## Achillion to Present At Upcoming Conferences

NEW HAVEN, Conn., Jun 2, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate overview and update on the Company's HCV programs at the following upcoming investment conferences:

- \* Noble Financial Capital Markets 5th Annual Emerging Growth Equity Conference -- June 9, 2009 at 1:20 p.m. at the Hard Rock Hotel in Hollywood, Florida
- \* Needham and Company 8th Annual Life Sciences Conference -- June 10, 2009 at 3:00 p.m. at the New York Palace Hotel in New York City

The live audio broadcasts and the subsequent archived webcasts of the Company presentation will be available on the Company's website, <http://www.achillion.com>, under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

### About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- hepatitis, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit the company's web site at [www.achillion.com](http://www.achillion.com). ACHN-G

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: Achillion Pharmaceuticals, Inc

Achillion Pharmaceuticals, Inc.  
Mary Kay Fenton  
(310) 691-7100  
[mfenton@achillion.com](mailto:mfenton@achillion.com)

Lippert/Heilshorn & Associates, Inc.  
Investors:  
Anne Marie Fields  
(212) 838-3777  
[afields@lhai.com](mailto:afields@lhai.com)

Bruce Voss  
(310) 691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX